The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
Open accessAbstract
Background: Despite the fact that obesity and overweight are serious major health problems worldwide, fighting against them is also considered a challenging issue. Several interventional studies have evaluated the potential weight-reduction effect of Tirzepatide. In order to obtain a better viewpoint from them, this study aimed to comprehensively investigate the effects of subcutaneous Tirzepatide on obesity and overweight. Methods: Scopus, PubMed/Medline, Web of Science, Cochrane, and Embase databases were searched using standard keywords to identify all controlled trials investigating the weight loss effects of Tirzepatide. Pooled weighted mean difference and 95% confidence intervals were achieved by random-effects model analysis for the best estimation of outcomes. The statistical heterogeneity and publication bias were determined using the Cochran’s Q test and I 2 statistics and using the funnel plot and Egger’s test, respectively. Results: Twenty three treatments arm with 7062 participants’ were included in this systematic review and meta‐regression analysis. The pooled findings showed that Tirzepatide vs placebo significantly reduced body weight (weighted mean difference (WMD): -11.34 kg, 95% confidence interval (CI): -12.79 to -9.88, P< 0.001), body mass index (BMI) (WMD: -3.11 kg/m2, 95% CI: -4.36 to -1.86, P< 0.001), and waist circumference (WC) (WMD: -7.24 cm, 95% CI -10.12 to -4.36, P< 0.001). These reductions were even greater, especially with higher doses and duration of Tirzepatide. Conclusions: Tirzepatide medication had significant effects on weight management with the reduction of body weight, BMI, and WC. Administration of Tirzepatide can be considered a therapeutic strategy for overweight or obese people.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tirzepatide has shown significant effects on weight management with reductions in body weight, body mass index, and waist circumference in patients with obesity or diabetes.
“Tirzepatide has shown significant effects on weight management with the reductions in body weight, body mass index (BMI), and waist circumference (WC) in patients with obesity or diabetes [23].”
From The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · see citing works
Estimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062 · see citing works
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2× · see citing works
“2022 (32) Multicenter (Countries not reported) 3 Obesity 45 32.”
ResultTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · see citing works
The genetics of obesity: From discovery to biology
Loos, R. J. F., & Yeo, G. S. H. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00414-z · Cited by 1,291 · see citing works
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · see citing works
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 2× · see citing works
“SGLT-2 I causes a statistically significant decrease in body weight and, in a dose-dependent manner, increases urine glucose excretion (55).”
BackgroundRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · see citing works
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · see citing works
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684 · see citing works
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · see citing works
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597 · see citing works
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1× · see citing works
“Despite some of the gastrointestinal adverse events of Tirzepatide including nausea, vomiting, and diarrhea (6, 24, 25), it has superiority to other similar agents and is considered a promising anti-obesity therapeutic drug due to its multiple pharmacological targets on nutrient-stimulated hormone receptor agonists (6…”
BackgroundGastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513 · see citing works
Bolinder, J., Ljunggren, Ö., Johansson, L. O. M., Wilding, J. P. H., Langkilde, A., Sjöström, C. D., Sugg, J. E., & Parikh, S. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 488 · see citing works
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419 · see citing works
Multifactorial causation of obesity: implications for prevention
Grundy, S. M. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.3.563s · Cited by 403 · see citing works
Regulation of Body Weight in Humans
Jéquier, E., & Tappy, L. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.2.451 · Cited by 369 · see citing works
Schwingshackl, L., Knüppel, S., Schwedhelm, C., Hoffmann, G., Missbach, B., Stelmach-Mardas, M., Dietrich, S., Eichelmann, F., Kontopanteils, E., Iqbal, K., et al. (2016) · Advances in Nutrition · doi:10.3945/an.116.013052 · Cited by 360 · see citing works
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345 · see citing works
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272 · see citing works
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268 · see citing works
Min, T., & Bain, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 261 · see citing works
Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022) · Molecules · doi:10.3390/molecules27134315 · Cited by 208 · see citing works
Wilson, J. M., Lin, Y., Luo, M. J., Considine, G., Cox, A. L., Bowsman, L. M., Robins, D. A., Haupt, A., Duffin, K. L., & Ruotolo, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14553 · Cited by 149 · see citing works
Liraglutide: A New Option for the Treatment of Obesity
Nuffer, W. A., & Trujillo, J. M. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1639 · Cited by 148 · see citing works
Fisman, E. Z., & Tenenbaum, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01412-5 · Cited by 124 · see citing works
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121 · see citing works
Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
Lu, V. B., Gribble, F. M., & Reimann, F. M. (2021) · Nutrients · doi:10.3390/nu13030883 · Cited by 105 · see citing works
Frederick, M. O., Boyse, R. A., Braden, T. M., Calvin, J. R., Campbell, B. M., Changi, S. M., Coffin, S. R., Condon, C., Gowran, O., Groh, J. M., et al. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00108 · Cited by 96 · see citing works
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77 · cited 1× · see citing works
“It is probable that the successful application of incretin peptide hormones has the potential to reduce weight and consider an obesity treatment (13, 14).”
BackgroundEfficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Zhong, P., Zeng, H., Huang, M., Fu, W., & Chen, Z. (2022) · Endocrine · doi:10.1007/s12020-021-02945-1 · Cited by 74 · see citing works
Wolever, T., Chiasson, J.-L., Josse, R., Hunt, J., Palmason, C., Rodger, N., Ross, S., Ryan, E., & Tan, M. (1997) · International Journal of Obesity · doi:10.1038/sj.ijo.0800468 · Cited by 71 · see citing works
Kassie, A. M., Abate, B. B., & Kassaw, M. W. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039200 · Cited by 71 · see citing works
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J. M., Miller‐Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 69 · see citing works
Ryan, D. H. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21033 · Cited by 67 · see citing works
Bhagavathula, A. S., Vidyasagar, K., & Tesfaye, W. H. (2021) · Pharmaceuticals · doi:10.3390/ph14100991 · Cited by 60 · see citing works
Wang, L. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s358989 · Cited by 56 · see citing works
Pharmacotherapy of obesity: An update
Cignarella, A., Busetto, L., & Vettor, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105649 · Cited by 53 · see citing works
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Tall Bull, S., Nuffer, W., & Trujillo, J. M. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108332 · Cited by 43 · see citing works
Moon, S., Lee, J., Chung, H. S., Kim, Y. J., Yu, J. M., Yu, S. H., & Oh, C.-M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.934 · Cited by 38 · see citing works
Kaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 35 · see citing works
Arastu, N., Cummins, O., Uribe, W., & Nemec, E. C. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01428-1 · Cited by 33 · see citing works
Barboza, J. J., Huamán, M. R., Melgar-Talavera, B., Diaz‐Arocutipa, C., Valenzuela-Rodríguez, G., & Hernández, A. V. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11112998 · Cited by 33 · see citing works
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 21 · see citing works
Updates on Monogenic Obesity in a Multifactorial Disease
Baxter, J., Armijo, P. R., Flores, L. E., Krause, C. M., Samreen, S., & Tanner, T. N. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04200-z · Cited by 18 · see citing works
Oladeji, O., Zhang, C., Moradi, T., Tarapore, D., Stokes, A., Marivate, V. N., Sengeh, D. M., & Nsoesie, E. O. (2021) · JMIR Public Health and Surveillance · doi:10.2196/24348 · Cited by 17 · see citing works
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2
Al‐Horani, R. A., & Chedid, M. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666221004151212 · Cited by 12 · see citing works
Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
Ali, R., Virendra, S. A., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100032 · Cited by 11 · see citing works
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Singh, M. (2022) · Annals of Internal Medicine · doi:10.7326/j22-0009 · Cited by 2 · see citing works
Understanding the underlying drivers of obesity in Africa: a scoping review protocol
Jaca, A., Iwu, C. J., Durão, S., Onyango, A. W., & Wiysonge, C. S. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040940 · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [2]Pugliese G Liccardi A Graziadio C Barrea L Muscogiuri G Colao A. Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. Int J Obes (2005) 46(3): 449–65. doi: 10.1038/s41366-021-01035-6 35058571 · DOI
- [43]Farzam K Patel P. Tirzepatide. In: StatPearls [Internet]. StatPearls Publishing (2022). 36251836
Cited by
Sorted by citations
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050668 · Cited by 19 · see citing works
- Authors
- Rohani, P., Malekpour Alamdari, N., Bagheri, S. E., Hekmatdoost, A., & Sohouli, M. H.
- Affiliations
- Children's Medical Center (IR)
- Tehran University of Medical Sciences (IR)
- Shahid Beheshti University (IR)
- Corresponding author
- Sohouli, Mohammad Hassan
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-08-09
- Volume
- 14
- Pages
- 1230206-1230206
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC10446893
- OpenAlex
- W4385693632
- Cited by
- 18
- References
- 53
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 1
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, obesity, overweight, weight loss, body mass index, waist circumference, subcutaneous administration, GLP-1 receptor agonists, weight management
- MeSH terms
- Tirzepatide, Body Weight, Humans, Obesity, Regression Analysis, Randomized Controlled Trials as Topic, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
